haroutine liposomal glutathione Pure Encapsulations Liposomal Glutathione - 30 CT

2.9 Lactate dehydrogenase (LDH) assay Briefly, 50 L from the apical chamber of GDC-treated monolayers were transferred to a 96-well flat-bottom plate, and mixed with equal volume of LDH Cytotoxicity Assay reaction mixture

The experiment was terminated on day 124 post-injection based on humane endpoint considerations, and mice were sacrificed at this time point for subsequent analyses

However, the largest Phase IIb trial involving 536 participants failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading to development termination in 2007

Whether that theoretical advantage translates to clinical benefit remains unproven